Almost every GLP-1 drug you have heard of is a peptide, with all the injection-or-difficult-oral-delivery baggage that implies. US11851419B2 - "GLP-1R modulating compounds," issued December 26, 2023 to Gilead Sciences, Inc. - claims a different answer: small molecules.

The CPC class is the immediate tell. The grant sits in C07D 401/14 and related C07D heterocyclic-compound classes - the small-molecule chemistry buckets - not in C07K, the peptide-and-protein classes where semaglutide, tirzepatide, and their kin live. That single classification difference signals an entirely separate chemical lineage and prior-art pool, and it shapes how the claims are drawn.

"The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human."- U.S. Patent No. 11,851,419 source

Claim 1 is the structural heart of the grant, and it is worth being precise about its form: it claims a compound, or a pharmaceutically acceptable salt thereof, defined by a depicted chemical structure. In the issued claim that structure is a specific drawn formula - rendered in the record as chemical-structure figures rather than a wide Markush variable set. That is a meaningful teardown detail: claim 1 reads as a defined-compound (or tightly drawn) composition-of-matter claim, not a sprawling genus with dozens of substituent positions left open. The enforceable edge of a claim like this is the chemical structure itself; its scope is as broad, and only as broad, as the depicted compound and its pharmaceutically acceptable salts.

The dependent claims build the expected pharmaceutical scaffolding around that compound. Claim 2 recites a pharmaceutical composition comprising a pharmaceutically effective amount of the claim-1 compound plus a carrier or excipient. Claims 3 and 4 reach combination products: the composition "further comprising one or more additional therapeutic agents," and then an enumerated list of anti-obesity co-agents - peptide YY, NPYR2/NPYR1 agonists, CB1R antagonists, lipase inhibitors, MC4R agonists, SGLT2/SGLT1 inhibitors, amylin, leptin, a glucagon-receptor agonist (alone or with another GLP-1R agonist), and many more. Those combination claims are a strategic perimeter: they anticipate that a small-molecule GLP-1R agonist will be paired with other metabolic agents, and they stake the pairings in advance.

Why does the chemistry distinction matter for scope and value? A small-molecule GLP-1R agonist is the kind of structure that can in principle be delivered as a true oral tablet without the elaborate formulation peptides require. The claimed invention is the chemical structure that modulates the receptor; the inventive limitation is composition of matter. The claim-construction question is therefore a medicinal-chemistry one - is an accused compound the depicted structure or a pharmaceutically acceptable salt of it - rather than a method-of-use question. Composition-of-matter claims of this type are the strongest currency in pharma IP precisely because they reach the molecule wherever it appears, regardless of indication.

It is worth being explicit about why a composition-of-matter claim drawn to a depicted structure behaves so differently from the method claims that dominate much of the metabolic estate. A method-of-use claim is infringed only by performing the method; a composition claim of the kind in claim 1 is infringed by making, using, selling, or importing the compound itself, whatever the stated purpose. That is the most durable form of pharmaceutical exclusivity, and it is why the structural definition - not the "GLP-1R agonist" label - is the asset here. The label describes utility; the drawn structure is the property line.

The combination claims deserve a closer read because they reveal strategic intent. Claim 3 reaches a composition "further comprising one or more additional therapeutic agents," and claim 4 then enumerates a long anti-obesity roster: peptide YY, NPYR2 and NPYR1 agonists and NPYR5 antagonists, a CB1R antagonist, lipase inhibitors, MC4R agonists, FXR agonists, SGLT2/SGLT1 and dual SGLT2/SGLT1 inhibitors, amylin, leptin, a glucagon-receptor agonist (alone or with another GLP-1R agonist), and more. By staking these pairings, the patentee anticipates that a small-molecule GLP-1R core will, in practice, be combined with adjacent metabolic mechanisms - and claims the combinations before competitors can. For a freedom-to-operate analyst, that means the relevant question is not only "is my compound the claimed structure?" but "does my fixed-dose combination read on a claimed pairing?"

The teardown framing, then, is that this is a tightly drawn composition-of-matter grant with a combination perimeter built around it. Its enforceable edge is chemical: an accused molecule either is, or is not, the depicted compound or a pharmaceutically acceptable salt of it. Unlike the sequence-and-activity claims that characterize the peptide and oligonucleotide grants elsewhere in this series, there is no functional-activity hurdle to clear in claim 1 - the structure is the limitation, full stop, which is exactly what makes small-molecule composition claims the cleanest to enforce and the hardest to design around within their structural reach.

One further teardown nuance: because claim 1 depicts a structure rather than reciting a broad variable genus, the prosecution and validity story for a grant like this turns on whether that specific compound was novel and non-obvious over the prior small-molecule GLP-1R art, not over the peptide art at all. The two prior-art pools scarcely touch. A challenger attacking the claim would search the C07D heterocyclic-agonist literature for the depicted scaffold and its close analogs; the existence of semaglutide or tirzepatide is essentially irrelevant to that inquiry, because those are C07K peptides built from a different chemical playbook. That separation is precisely why oral small-molecule GLP-1R chemistry is treated as its own field for both validity and freedom-to-operate.

For the landscape, the small-molecule GLP-1R neighborhood is a strategically important white space relative to the peptide estate. It is chemically distinct, faces different prior art, and offers the oral-tablet prize that peptides struggle to match. A freedom-to-operate map for metabolic drugs has to treat C07D small-molecule GLP-1R claims as a separate field from the C07K peptide claims - they barely overlap in structure - while watching the combination claims, which extend a small-molecule core into the broader metabolic-cocktail space where many programs ultimately compete.